Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Genetics (clinical),Neurology (clinical)
Reference73 articles.
1. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis
2. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up
3. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
4. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis
Cited by 46 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis;Neurology and Therapy;2024-09-04
2. Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions;Multiple Sclerosis and Related Disorders;2024-08
3. De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis;Current Neurology and Neuroscience Reports;2024-07-12
4. Ocrelizumab-induced organizing pneumonia in multiple sclerosis: case report and literature review;Archive of Clinical Cases;2024-06-30
5. Escalating to medium‐ versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosis;Brain and Behavior;2024-04-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3